ReviewFrontiers in genetics2025
Current progress and future perspective of super-enhancers: a viable and effective bridge between the transcriptional apparatus and disease.
Review in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From cell to disease: Regulatory networks and mechanisms of super‑enhancers in aging (Review).Molecular medicine reports · 2026Review
- MiRNAs in hyperglycemia-induced metabolic memory: established mechanisms and emerging nuclear activation concepts.Diabetology & metabolic syndrome · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Super-enhancers are a super-cluster of enhancers formed by serially arranged regulatory elements that can strongly drive the expression of cell-related genes. Hundreds of SEs in cells affect cell identity and fate-determining processes. Previous studies have verified that the expression of pathogenic genes is highly correlated with the abnormal activation of SEs in malignant tumorigenesis, dementia, diabetes, and many autoimmune diseases. Also, enhancer RNAs (eRNAs) can be regarded as crucial markers for SEs. Here, we summarize the discovery process and basic concepts of SEs, describe the structural characteristics and functional regulation of SEs in different tumor diseases, Alzheimer's disease, and immune-related diseases, with a focus on typical diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. In this review, we also discuss the potential clinical applications of SE, as well as the research prospects in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.